In vivo CAR T cell engineering: design principles and open questions
Delivering CAR T cell engineering directly inside patients could eventually expand access to this powerful cancer treatment by avoiding expensive, complex manufacturing outside the body.
This review from Dana-Farber/MIT summarizes state-of-the-art approaches for engineering CAR T cells directly inside patients using targeted viral vectors and lipid nanoparticles, circumventing the complex and expensive ex vivo manufacturing process that currently limits access. Early clinical studies show safety and preliminary efficacy, though long-term durability, optimal delivery routes, and ideal disease indications remain open questions.
What the study was
- Study design
- Narrative review of preclinical and clinical data
- Population
- Patients with hematologic malignancies receiving CAR-T therapy
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Trends in Cancer
Why it surfaced
In vivo CAR-T engineering represents a potentially transformative shift in adoptive cell therapy delivery — if validated, it could democratize CAR-T access globally by eliminating costly ex vivo manufacturing. Review from leading centers (Dana-Farber, MIT) synthesizing viral and nonviral in vivo reprogramming with early clinical signals. Elevated to HIGH by NOVEL_TREATMENT flag despite review study design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.